肾上腺素联合血管加压素与糖皮质激素在心脏骤停中的应用(VAST-A)——一项随机先导研究
VAST-A为随机、双盲、安慰剂对照先导研究,2022年12月至2024年6月在瑞典三家医院纳入39例目击院内心脏骤停患者,1:1随机接受肾上腺素+血管加压素+糖皮质激素(干预组16例)或肾上腺素+安慰剂(对照组23例)。主要终点为可行性(方案依从性、事件时间、入组率)与安全性,次要终点为自主循环恢复。干预组自主循环恢复6/16(38%),对照组4/23(17%)。结论认为随机分组安全,但需改善可行性以达到主研究入组目标。
要点
- 39例目击院内心脏骤停患者随机分组:干预组16例接受肾上腺素+血管加压素+糖皮质激素,对照组23例接受肾上腺素+安慰剂。
- 入组率为0.8例/医院床位/月;多数心脏骤停发生在普通病房(17/39,44%)。
- 肾上腺素给药中位时间:干预组7:00(IQR 3:00-10:00)vs 对照组5:00(IQR 2:30-8:30);血管加压素/安慰剂给药中位时间:干预组10:30(IQR 9:30-12:15)vs 对照组9:00(IQR 5:00-11:00)。
- 自主循环恢复:干预组38%(6/16)vs 对照组17%(4/23)。
- 可行性分析中,4例在骤停现场、3例在ICU发生方案偏离;结论认为随机分组安全,但可行性需改善以满足主研究入组。
适用人群与场景
- 目击的院内心脏骤停(IHCA)且符合肾上腺素使用标准的患者,来自瑞典三家医院,2022年12月至2024年6月。
处置流程与药物剂量
- 干预组:肾上腺素、血管加压素与糖皮质激素联合使用;对照组:肾上腺素与安慰剂;随机分组为1:1,双盲设计。
研究设计与关键结果
- 随机、双盲、安慰剂对照先导研究,三家瑞典医院,筛查183例IHCA,随机39例(干预组16例,对照组23例),中位年龄77岁,64%男性。
- 入组率0.8例/医院床位/月;多数心脏骤停发生在普通病房(17/39,44%)。
- 可行性分析中,4例在骤停现场、3例在ICU发生方案偏离;从心脏骤停到快速反应团队到达的中位时间两组相似。
- 肾上腺素给药中位时间:干预组7:00(IQR 3:00-10:00)vs 对照组5:00(IQR 2:30-8:30);血管加压素/安慰剂给药中位时间:干预组10:30(IQR 9:30-12:15)vs 对照组9:00(IQR 5:00-11:00)。
- 自主循环恢复:干预组38%(6/16)vs 对照组17%(4/23)。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照先导研究(NCT05139849)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在院内心脏骤停中随机给予肾上腺素、血管加压素与糖皮质激素联合治疗相比对照组是安全的,但可行性需改善以达到VAST-A主研究的充分入组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The potential benefit of combining adrenaline, vasopressin, and corticosteroids in in-hospital cardiac arrest (IHCA) needs to be confirmed in a large clinical trial. This pilot study assesses feasibility and safety of randomising patients to this combination therapy compared to standard care.
MATERIAL AND METHODS: A randomised, double-blind, placebo-controlled pilot study was conducted from December 2022 to June 2024 across three Swedish hospitals (NCT05139849). Witnessed IHCAs meeting criteria for adrenaline were randomised 1:1 to adrenaline, vasopressin, and corticosteroids (intervention) or adrenaline and placebo (control). Primary outcomes included feasibility (e.g., protocol adherence, event times, enrolment rate), and safety. Secondary outcome was return of spontaneous circulation.
RESULTS: Of 183 screened IHCAs, 39 patients (median age 77, 64% male) were randomised (16 intervention, 23 control), with an enrolment rate of 0.8 patients/hospital bed/month. Most cardiac arrests occurred in general wards (n = 17/39, 44%). In the feasibility analysis, four patients at the scene of the arrest and three patients in the intensive care unit experienced protocol deviations. Median time (minutes) from cardiac arrest to rapid response team arrival was similar between groups. Median time to adrenaline administration was 7:00 (IQR 3:00-10:00) (intervention) vs 5:00 (IQR 2:30-8:30) (control) and to vasopressin/placebo 10:30 (IQR 9:30-12:15) vs 9:00 (IQR 5:00-11:00). Return of spontaneous circulation occurred in 38% (6/16) in the intervention group and 17% (4/23) in controls.
CONCLUSION: In this IHCA pilot study, randomisation to adrenaline, vasopressin, and corticosteroids compared to controls was safe, but feasibility needs improvement for adequate enrolment in the VAST-A main study.
参考来源
- Albert M, Forsberg S, Ringh M, et al. Vasopressin and steroids in addition to adrenaline in cardiac arrest (VAST-A) - A randomised pilot study. Resuscitation. 2025. PMID: 40154876. doi:10.1016/j.resuscitation.2025.110593
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。